Deemed a putative tumor suppressor in breast cancer, the tight junction protein claudin 1 has now been shown to be highly expressed in the basal-like molecular subtype. Moreover, recent in vitro studies show that claudin 1 can regulate breast cancer cell motility and proliferation. Herein, we investigated whether microRNA (miRNA) dysregulation is associated with alterations in the level of claudin 1. Using next-generation sequencing (NGS), we identified seven miRNAs (miR-9-5p, miR-9-3p, let-7c, miR-127-3p, miR-99a-5p, miR-129-5p, and miR-146a-5p) that were deregulated as a consequence of claudin 1 overexpression in the MDA-MB231 human breast cancer (HBC) cell line. Most of these miRNAs have been associated with tumor suppression in a variety of cancers, including breast cancer. Moreover, through gene expression profiling analysis, we identified epithelial–mesenchymal transition-related genes, including platelet-derived growth factor receptor-beta (PDGFRB) and cadherin 1 (CDH1, E cadherin), whose downregulation correlated with claudin 1 overexpression. Collectively, we show for the first time that in HBC, claudin 1 can alter the dynamics of a number of miRNAs involved in tumor progression. Our data suggest that the dysregulated expression of these miRNAs, in conjunction with the high claudin 1 levels, could serve as a useful biomarker that identifies a subset of tumors within the poorly characterized basal-like subtype of breast cancer. Further studies are warranted to determine the role of these miRNAs in facilitating the function of claudin 1 in breast cancer.
Get full access to this article
View all access options for this article.
References
1.
AgarwalR., MoriY., ChengY., JinZ., OlaruA.V., HamiltonJ.P., DavidS., SelaruF.M., YangJ., AbrahamJ.M., MontgomeryE., MorinP.J., and MeltzerS.J. (2009). Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS One, 4, e8002.
2.
AndertonJ.A., LindseyJ.C., LusherM.E., GilbertsonR.J., BaileyS., EllisonD.W., and CliffordS.C. (2008). Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol, 10, 981–994.
3.
BandresE., AgirreX., BitarteN., RamirezN., ZarateR., Roman-GomezJ., ProsperF., and Garcia-FoncillasJ. (2009). Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer, 125, 2737–2743.
BertoliG., CavaC., and CastiglioniI. (2015). MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics, 5, 1122–1143.
6.
BerxG., and van RoyF. (2001). The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res, 3, 289–293.
7.
BjornerS., FitzpatrickP.A., LiY., AllredC., HowellA., RingbergA., OlssonH., MillerC.J., AxelsonH., and LandbergG. (2014). Epithelial and stromal microRNA signatures of columnar cell hyperplasia linking Let-7c to precancerous and cancerous breast cancer cell proliferation. PLoS One, 9, e105099.
8.
BlanchardA.A., MaX., DueckK.J., PennerC., CooperS.C., MulhallD., MurphyL.C., LeygueE., and MyalY. (2013). Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer, 13, 268.
9.
BlanchardA.A., SklirisG.P., WatsonP.H., MurphyL.C., PennerC., TomesL., YoungT.L., LeygueE., and MyalY. (2009). Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch, 454, 647–656.
10.
BlankenbergD., Von KusterG., CoraorN., AnandaG., LazarusR., ManganM., NekrutenkoA., and TaylorJ. (2010). Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol Chapter 19, Unit 19.101–21.
11.
BockmeyerC.L., ChristgenM., MullerM., FischerS., AhrensP., LangerF., KreipeH., and LehmannU. (2011). MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat, 130, 735–745.
12.
Brunet VegaA., PericayC., MoyaI., FerrerA., DotorE., PisaA., CasalotsA., Serra-AracilX., OlivaJ.C., RuizA., and SaigiE. (2013). microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep, 30, 320–326.
13.
CaiW.Y., WeiT.Z., LuoQ.C., WuQ.W., LiuQ.F., YangM., YeG.D., WuJ.F., ChenY.Y., SunG.B., LiuY.J., ZhaoW.X., ZhangZ.M., and LiB.A. (2013). The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J Cell Sci, 126, 2877–2889.
14.
Calvano FilhoC.M., Calvano-MendesD.C., CarvalhoK.C., MacielG.A., RicciM.D., TorresA.P., FilassiJ.R., and BaracatE.C. (2014). Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol, 35, 7733–7741.
15.
ChenD., SunY., YuanY., HanZ., ZhangP., ZhangJ., YouM.J., Teruya-FeldsteinJ., WangM., GuptaS., HungM.C., LiangH., and MaL. (2014). miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. PLoS Genet, 10, e1004177.
16.
ChenJ., WangM., GuoM., XieY., and CongY.S. (2013). miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One, 8, e80266.
17.
ChenX., HuH., GuanX., XiongG., WangY., WangK., LiJ., XuX., YangK., and BaiY. (2012). CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer, 130, 1607–1613.
18.
CurtisC., ShahS.P., ChinS.F., TurashviliG., RuedaO.M., DunningM.J., SpeedD., LynchA.G., SamarajiwaS., YuanY., GrafS., HaG., HaffariG., BashashatiA., RussellR., McKinneyS., LangerodA., GreenA., ProvenzanoE., WishartG., PinderS., WatsonP., MarkowetzF., MurphyL., EllisI., PurushothamA., Borresen-DaleA.L., BrentonJ.D., TavareS., CaldasC., and AparicioS. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486, 346–352.
19.
DhawanP., SinghA.B., DeaneN.G., NoY., ShiouS.-R., SchmidtC., NeffJ., WashingtonM.K., and BeauchampR.D. (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest, 115, 1765–1776.
20.
DuanL., HaoX., LiuZ., ZhangY., and ZhangG. (2014). MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET. FEBS Lett, 588, 1644–1651.
21.
DuffyM.J., McGowanP.M., HarbeckN., ThomssenC., and SchmittM. (2014). uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res, 16, 428.
22.
DweepH., and GretzN. (2015). miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods, 12, 697.
23.
DyrskjotL., OstenfeldM.S., BramsenJ.B., SilahtarogluA.N., LamyP., RamanathanR., FristrupN., JensenJ.L., AndersenC.L., ZiegerK., KauppinenS., UlhoiB.P., KjemsJ., BorreM., and OrntoftT.F. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res, 69, 4851–4860.
24.
EwingB., and GreenP. (1998). Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res, 8, 186–194.
25.
EwingB., HillierL., WendlM.C., and GreenP. (1998). Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res, 8, 175–185.
26.
FuksiewiczM., KaminskaJ., KotowiczB., KowalskaM., RubachM., and PienkowskiT. (2006). Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clin Chem Lab Med, 44, 1092–1097.
27.
FuruseM., HataM., FuruseK., YoshidaY., HaratakeA., SugitaniY., NodaT., KuboA., and TsukitaS. (2002). Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol, 156, 1099–1111.
28.
GoecksJ., NekrutenkoA., TaylorJ., and GalaxyT. (2010). Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol, 11, R86.
29.
GrimmC., KantelhardtE., HeinzeG., PolterauerS., ZeillingerR., KolblH., ReinthallerA., and HeflerL. (2009). The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study. BMC Cancer, 9, 78.
30.
GuptaG.P., and MassaguéJ. (2006). Cancer metastasis: building a framework. Cell, 127, 679–695.
31.
HackenbergM., Rodriguez-EzpeletaN., and AransayA.M. (2011). miRanalyzer: an update on the detection and analysis of microRNAs in high-throughput sequencing experiments. Nucleic Acids Res, 39, W132–W138.
32.
Heerma van VossM.R., van DiestP.J., SmoldersY.H., BartJ., van der WallE., and van der GroepP. (2014). Distinct claudin expression characterizes BRCA1-related breast cancer. Histopathology, 65, 814–827.
33.
HerschkowitzJ.I., SiminK., WeigmanV.J., MikaelianI., UsaryJ., HuZ., RasmussenK.E., JonesL.P., AssefniaS., ChandrasekharanS., BacklundM.G., YinY., KhramtsovA.I., BasteinR., QuackenbushJ., GlazerR.I., BrownP.H., GreenJ.E., KopelovichL., FurthP.A., PalazzoJ.P., OlopadeO.I., BernardP.S., ChurchillG.A., Van DykeT., and PerouC.M. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol, 8, R76.
34.
HewittK.J., AgarwalR., and MorinP.J. (2006). The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer, 6, 186.
35.
HuY., ZhuQ., and TangL. (2014). MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One, 9, e92099.
36.
HuangY.W., LiuJ.C., DeatherageD.E., LuoJ., MutchD.G., GoodfellowP.J., MillerD.S., and HuangT.H. (2009). Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res, 69, 9038–9046.
37.
HurstD.R., EdmondsM.D., ScottG.K., BenzC.C., VaidyaK.S., and WelchD.R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res, 69, 1279–1283.
38.
JakopovicM., ThomasA., BalasubramaniamS., SchrumpD., GiacconeG., and BatesS.E. (2013). Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol, 3, 261.
39.
KangH.S., KimJ., JangS.G., KwonS.Y., ParkY.S., GreenJ.E., KimH.K., and RoJ. (2014). MicroRNA signature for HER2-positive breast and gastric cancer. Anticancer Res, 34, 3807–3810.
40.
KominskyS.L., ArganiP., KorzD., EvronE., RamanV., GarrettE., ReinA., SauterG., KallioniemiO.-P., and SukumarS. (2003). Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene, 22, 2021–2033.
41.
KuoY.Z., TaiY.H., LoH.I., ChenY.L., ChengH.C., FangW.Y., LinS.H., YangC.L., TsaiS.T., and WuL.W. (2014). MiR-99a exerts anti-metastasis through inhibiting myotubularin-related protein 3 expression in oral cancer. Oral Dis, 20, e65–e75.
42.
LeotlelaP.D., WadeM.S., DurayP.H., RhodeM.J., BrownH.F., RosenthalD.T., DissanayakeS.K., EarleyR., IndigF.E., NickoloffB.J., TaubD.D., KallioniemiO.P., MeltzerP., MorinP.J., and WeeraratnaA.T. (2007). Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene, 26, 3846–3856.
43.
LiH., XieS., LiuM., ChenZ., LiuX., WangL., LiD., and ZhouY. (2014). The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol, 45, 197–208.
44.
LivakK.J., and SchmittgenT.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402–408.
45.
Lopes-RamosC.M., Habr-GamaA., Quevedo BdeS., FelicioN.M., BettoniF., KoyamaF.C., AsprinoP.F., GalanteP.A., Gama-RodriguesJ., CamargoA.A., PerezR.O., and ParmigianiR.B. (2014). Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics, 7, 68.
46.
LuS., SinghK., MangrayS., TavaresR., NobleL., ResnickM.B., and YakirevichE. (2013). Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol, 26, 485–495.
47.
MaL., YoungJ., PrabhalaH., PanE., MestdaghP., MuthD., Teruya-FeldsteinJ., ReinhardtF., OnderT.T., ValastyanS., WestermannF., SpelemanF., VandesompeleJ., and WeinbergR.A. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol, 12, 247–256.
48.
MajerA., CaligiuriK.A., and BoothS.A. (2013). A user-friendly computational workflow for the analysis of microRNA deep sequencing data. Methods Mol Biol, 936, 35–45.
49.
MatamalaN., VargasM.T., Gonzalez-CamporaR., MinambresR., AriasJ.I., MenendezP., Andres-LeonE., Gomez-LopezG., YanowskyK., Calvete-CandenasJ., Inglada-PerezL., Martinez-DelgadoB., and BenitezJ. (2015). Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem, 61, 1098–1106.
50.
MehlenP., and PuisieuxA. (2006). Metastasis: a question of life or death. Nat Rev Cancer, 6, 449–458.
51.
MengF., SpeyerC.L., ZhangB., ZhaoY., ChenW., GorskiD.H., MillerF.R., and WuG. (2015). PDGFRalpha and beta play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. Cancer Res, 75, 584–593.
52.
MichlP., BarthC., BuchholzM., LerchM.M., RolkeM., HolzmannK.H., MenkeA., FenstererH., GiehlK., LohrM., LederG., IwamuraT., AdlerG., and GressT.M. (2003). Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res, 63, 6265–6271.
53.
MoritaK., FuruseM., FujimotoK., and TsukitaS. (1999). Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A, 96, 511–516.
54.
MorohashiS., KusumiT., SatoF., OdagiriH., ChibaH., YoshiharaS., HakamadaK., SasakiM., and KijimaH. (2007). Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med, 20, 139–143.
55.
MyalY., LeygueE., and BlanchardA.A. (2010). Claudin 1 in breast tumorigenesis: revelation of a possible novel “claudin high” subset of breast cancers. J Biomed Biotechnol, 2010, 956897.
56.
NegriniM., SabbioniS., HaldarS., PossatiL., CastagnoliA., CoralliniA., Barbanti-BrodanoG., and CroceC.M. (1994). Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res, 54, 1818–1824.
57.
PantschenkoA.G., PushkarI., AndersonK.H., WangY., MillerL.J., KurtzmanS.H., BarrowsG., and KreutzerD.L. (2003). The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol, 23, 269–284.
58.
PaulssonJ., EhnmanM., and OstmanA. (2014). PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol, 10, 1695–1708.
59.
PerouC.M., SørlieT., EisenM.B., van de RijnM., JeffreyS.S., ReesC.A., PollackJ.R., RossD.T., JohnsenH., AkslenL.A., FlugeO., PergamenschikovA., WilliamsC., ZhuS.X., LønningP.E., Børresen-DaleA.L., BrownP.O., and BotsteinD. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.
60.
PillaiM.M., GillenA.E., YamamotoT.M., KlineE., BrownJ., FloryK., HesselberthJ.R., and KabosP. (2014). HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res Treat, 146, 85–97.
61.
PopeJ.L., AhmadR., BhatA.A., WashingtonM.K., SinghA.B., and DhawanP. (2014). Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis. Mol Cancer, 13, 167.
62.
PratA., ParkerJ.S., KarginovaO., FanC., LivasyC., HerschkowitzJ.I., HeX., and PerouC.M. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res, 12, R68.
63.
RodriguesL.R., TeixeiraJ.A., SchmittF.L., PaulssonM., and Lindmark-ManssonH. (2007). The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev, 16, 1087–1097.
64.
SabatierR., FinettiP., GuilleA., AdelaideJ., ChaffanetM., ViensP., BirnbaumD., and BertucciF. (2014). Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer, 13, 228.
65.
SakuraiM., MikiY., MasudaM., HataS., ShibaharaY., HirakawaH., SuzukiT., and SasanoH. (2012). LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol, 131, 101–106.
66.
SandhuR., ReinJ., D'ArcyM., HerschkowitzJ.I., HoadleyK.A., and TroesterM.A. (2014). Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis, 35, 2567–2575.
67.
SenguptaP.K., SmithE.M., KimK., MurnaneM.J., and SmithB.D. (2003). DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res, 63, 1789–1797.
68.
ShevdeL.A., DasS., ClarkD.W., and SamantR.S. (2010). Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med, 10, 71–81.
69.
ShiM., LiuD., DuanH., ShenB., and GuoN. (2010). Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev, 29, 785–799.
70.
SinghA.B., and DhawanP. (2015). Claudins and cancer: fall of the soldiers entrusted to protect the gate and keep the barrier intact. Semin Cell Dev Biol, 42, 58–65.
71.
SlatteryM.L., HerrickJ.S., Torres-MejiaG., JohnE.M., GiulianoA.R., HinesL.M., SternM.C., BaumgartnerK.B., PressonA.P., and WolffR.K. (2014). Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study. Carcinogenesis, 35, 1750–1759.
72.
SørlieT., PerouC.M., TibshiraniR., AasT., GeislerS., JohnsenH., HastieT., EisenM.B., van de RijnM., JeffreyS.S., ThorsenT., QuistH., MateseJ.C., BrownP.O., BotsteinD., LønningP.E., and Børresen-DaleA.L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869–10874.
73.
SuhY., YoonC.H., KimR.K., LimE.J., OhY.S., HwangS.G., AnS., YoonG., GyeM.C., YiJ.M., KimM.J., and LeeS.J. (2013). Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene, 32, 4873–4882.
74.
SunQ., ZhaoX., LiuX., WangY., HuangJ., JiangB., ChenQ., and YuJ. (2014). miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate, 74, 1613–1621.
75.
TaubeJ.H., HerschkowitzJ.I., KomurovK., ZhouA.Y., GuptaS., YangJ., HartwellK., OnderT.T., GuptaP.B., EvansK.W., HollierB.G., RamP.T., LanderE.S., RosenJ.M., WeinbergR.A., and ManiS.A. (2010). Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A, 107, 15449–15454.
76.
TokésA.-M., KulkaJ., PakuS., SzikA., PáskaC., NovákP.K., SzilákL., KissA., BögiK., and SchaffZ. (2005). Claudin-1, −3 and −4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast cancer research: BCR, 7, R296–R305.
77.
TsukitaS., and FuruseM. (2002). Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol, 14, 531–536.
78.
TuckA.B., and ChambersA.F. (2001). The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia, 6, 419–429.
79.
Vincent-SalomonA., GruelN., LucchesiC., MacGroganG., DendaleR., Sigal-ZafraniB., LongyM., RaynalV., PierronG., de MascarelI., TarisC., Stoppa-LyonnetD., PiergaJ.Y., SalmonR., Sastre-GarauX., FourquetA., DelattreO., deC.P., and AuriasA. (2007). Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res, 9, R24.
80.
VoliniaS., GalassoM., SanaM.E., WiseT.F., PalatiniJ., HuebnerK., and CroceC.M. (2012). Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A, 109, 3024–3029.
81.
WangS., LiH., WangJ., WangD., YaoA., and LiQ. (2014). Prognostic and biological significance of microRNA-127 expression in human breast cancer. Dis Markers, 2014, 401986.
82.
WeigeltB., PeterseJ.L., and van't VeerL.J. (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer, 5, 591–602.
83.
XuB., WangN., WangX., TongN., ShaoN., TaoJ., LiP., NiuX., FengN., ZhangL., HuaL., WangZ., and ChenM. (2012). MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate, 72, 1171–1178.
84.
YangZ., HanY., ChengK., ZhangG., and WangX. (2014). miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells. Cell Prolif, 47, 587–595.
85.
YenY.C., ShiahS.G., ChuH.C., HsuY.M., HsiaoJ.R., ChangJ.Y., HungW.C., LiaoC.T., ChengA.J., LuY.C., and ChenY.W. (2014). Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer, 13, 6.
86.
YuX., SongH., XiaT., HanS., XiaoB., LuoL., XiY., and GuoJ. (2013). Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene, 532, 87–93.
87.
YuY., ZhaoY., SunX.H., GeJ., ZhangB., WangX., and CaoX.C. (2015). Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer. Oncotarget, 6, 34423–34436.
88.
YunJ., FrankenbergerC.A., KuoW.L., BoelensM.C., EvesE.M., ChengN., LiangH., LiW.H., IshwaranH., MinnA.J., and RosnerM.R. (2011). Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J, 30, 4500–4514.
89.
ZhangH., JiaR., WangC., HuT., and WangF. (2014). Piceatannol promotes apoptosis via up-regulation of microRNA-129 expression in colorectal cancer cell lines. Biochem Biophys Res Commun, 452, 775–781.
90.
ZhouB., BlanchardA., WangN., MaX., HanJ., SchroedterI., LeygueE., and MyalY. (2015). Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7. Cancer Invest, 33, 429–439.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
